Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors.

$RGBP Research Has Identified Non Toxic Compound Effective In Treating Auto Immune Diseases

|About: Regen BioPharma, Inc. (RGBP)
Summary

Auto Immune Diseases Treatment Discovery

Cancer

Rare Blood Diseases

Clinical Stage Stem Cell

www.regenbiopharmainc.com

Regen BioPharma, Inc. Research Demonstrates Ex-Vivo Immune Suppression With Novel NR2F6 Activators

PR Newswire July 25, 2017

Novel Activators Demonstrate Selective Inhibition of IL-17a and IL-2

SAN DIEGO, July 25, 2017 /PRNewswire/ --

Regen BioPharma Inc. (RGBP) and (RGBPP) today reported continued progress in Regen's development of small molecule drugs that activate and inhibit NR2F6. The Company reports that recently identified novel chemical compounds that activate NR2F6 also selectively inhibit cytokines secreted from activated immune cells. This indicates that researchers have identified a compound that appears to be effective in treating autoimmune diseases with virtually no toxicity. Research was conducted by ChemDiv, Inc. (an internationally recognized contract research organization) which has been retained by Regen to conduct research and experiments on Regen's behalf.

Read More:

Regen BioPharma, Inc. Research Demonstrates Ex-Vivo Immune Suppression With Novel NR2F6 Activators

Other Recent Events and Information:

$RGBP - Major Breakthrough - Discovers Compound 10X More Effective - Cancer-Killing Potential

(OTCQB:OTCQB:RGBP) Regen BioPharma, Inc. Sees New-Additional Positive Results for NR2F6 Checkpoint for Treating Cancer and Autoimmune Diseases 

Regen BioPharma, Inc. Announces the Company Canceled 31.5 Million Shares

Previous Items of Significance:

HemaXellerate’s approval and clearance by the FDA to commence Human Trials with the New Drug. That resulted in two things. One RGBP transitioned from a R&D company, morphing into a Clinical Trials Company, a major step in the progress of the company and credibility. Second RGBP attracted their first viable partner as the (NIH) agency NCATS agreed to collaborate with clinical trials using HemaXellerate for a treatment of the rare blood disease/disorder aPlastic Anemia. 

New Partners – NIH (NCATS) - Pan Am Cancer Research and Treatment Center - Eli Lily & Company – Weill Cornell Medical College (Cornell University) 

HemaXellerate II was discovered to be effective in treating an additional market much more vast than aPlastic Anemia. It is in the early stage of development to treat Bone Marrow Suppression, a common disorder due to Chemotherapy. This finding occurred at/with another new partner The Pan Am Cancer Research and Treatment Center where ongoing Trials are being conducted. 

Regen BioPharma Submits Application to FDA for Orphan Drug Designation for its HemaXellerate Product 

dCell Vax (Treatment for Breast Cancer) seems to be at last news in the final comments with the FDA to gain approval to commence Human Trials with Breast Cancer Patients. 

The NIH (NCATS) also is collaborating with Regen and working together to screen small molecule compounds that activate or inhibit orphan nuclear receptor, NR2F6 (Research Project), cell lines will be provided by Regen. Regen also has a partnership with Eli Lily working together with NR2F6. 

For all the news-Details on other treatments HemaXellerate I, HemaXellerate II, dCell Vax, NR2F6, Tcellvax, uCell Vax, Car-T Cell for various Cancers, Autoimmune, Rare Blood Disorders/Diseases, Leukemia, etc. visit Yahoo Finance, OTC Markets, or RGBP Web Site. 

We believe Regen BioPharma is a Long Play, with a great upside with all the items in its Pipeline. Very possibly a Buy Out Target.

RGBP also has Short Term Gain Potential that has been proven time and again since we began following them. Increases-Bounces in Share Pricing ranging from 30%-400% and more at various intervals.

If you have any questions concerning (OTCQB:OTCQB:RGBP) or have a need for more information, please feel free to contact me.

Robert E. Kreh - Principal

Small Cap Solutions, LLC

(443) 567-2609

robkreh@smallcapsolutions.com

robkreh@gmail.com


(OTCBB:RGBP) Disclaimer: You are receiving this because you have requested the information contained in this email, and/or have expressed an interest recently, or in the past to be included in such emails. And/or have requested information/news/updates for Regen BioPharma, Inc. This profile has been compiled by Small Cap Solutions, LLC based on information from the company believed to be true/factual. This profile is not guaranteed, neither implied, nor in writing, as to the accuracy and completeness of content, and prepared for information purposes only. As such, this profile may contain forward reaching statements, as defined in the Private Securities Litigation Act of 1995. Actual results could differ materially from the statements either expressed or implied herein. Prospective investors are advised to review the Company's periodic filings with the Securities and Exchange Commission or at www.otcmarkets.com. Small Cap Solutions, LLC has received ($1000.00) cash from Value Quest, Inc. for investor relations services rendered for Regen BioPharma, Inc. . Additional inquiries are available by email to robkreh@smallcapsolutions.com or in writing to Small Cap Solutions, LLC 303 Joppa Crossing Ct (Suite #1) Joppa, Md. 21085 This is not a solicitation to buy or sell securities. To "unsubscribe to this mailing list, please reply "unsubscribe" to this message.

Disclaimer: All Micro/Small Cap Company(ies) profile(S) are/have been compiled by Small Cap Solutions, LLC based on information believed to be true and gathered either from client companies and/or third party('s)/web sites. These profiles are not guaranteed, neither implied, nor in writing, as to the accuracy and completeness of content, and has been prepared for information purposes only. As such, this profile may contain forward reaching statements, as defined in the Private Securities Litigation Reform Act of 1995. Actual results could differ materially from the statements either expressed or implied herein.

Prospective investors are advised to review the Company's periodic filings with the Securities and Exchange Commission or at yahoofinance.com and/or otcmarkets.com Small Cap Solutions, LLC may receive cash or stock from client companies for investor relations services rendered.

Small Cap Solutions, LLC and/or its Principal/Employees are not registered Broker(S)/Broker Dealer(S) with FINRA or the SEC. Small Cap Solutions, LLC does not make any buy/sell recommendations at any time, but may state their opinion on companies, etc. That is not meant to be a recommendation. All information disseminated by Small Cap Solutions, LLC is believed to be true and public. Additional inquiries available by email to robkreh@smallcapsolutions.comor by mail to 303 Joppa Crossing Ct. (Suite#1) Joppa, Md. 21085. To unsubscribe to this mailing list, please reply "unsubscribe" to this message or by mail to 303 Joppa Crossing Ct. (Suite#1) Joppa, Md. 21085. To unsubscribe to this mailing list, please reply "unsubscribe" to this message.

Disclosure: I/we have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours.